MTOR and cancer: The common perturbation of mitogenic signalling axes such as MAPK or PI3K‐Akt‐mTOR has led to development of inhibitors of those axes, although those inhibitors have not been potent single‐agents,30, 31 therapies targeting cell cycle progression, the end‐point of proliferation cascades commonly activated in cancer,29, 32 are being actively investigated.